COMPARISON OF TWO DOSES OF CARBETOCIN WITH OXYTOCIN FOR THE PREVENTION OF POSTPARTUM BLEEDING
Not Applicable
Recruiting
- Conditions
- Postpartum haemorrhage
- Registration Number
- PACTR202204640411588
- Lead Sponsor
- Rasheedat Balogun
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 321
Inclusion Criteria
Healthy pregnant women at term
Exclusion Criteria
Women with history of, or being treated for bleeding disorder
Women with intrauterine fetal demise
Women with antepartum haemorrhage
Women requiring general anaesthesia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which carbetocin prevents postpartum haemorrhage compared to oxytocin?
How does the efficacy of different carbetocin doses compare to standard oxytocin in preventing postpartum haemorrhage?
Are there specific biomarkers that can predict which patients will respond best to carbetocin over oxytocin for postpartum haemorrhage prevention?
What are the known adverse events associated with carbetocin administration and how do they compare to oxytocin in postpartum care?
What other uterotonic agents or combination therapies are being explored as alternatives to carbetocin and oxytocin for postpartum haemorrhage prevention?